Page last updated: 2024-11-10

e 6123

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

E 6123: platelet activating factor antagonist [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID3035214
CHEMBL ID114014
MeSH IDM0186276

Synonyms (16)

Synonym
e 6123
brn 4280434
4h-pyrido(4',3':4,5)thieno(3,2-f)(1,2,4)triazolol(4,3-a)(1,4)diazepine, 6-(2-chlorophenyl)-9-(cyclopropylcarbonyl)-7,8,9,10-tetrahydro-1,4-dimethyl-, (s)-
4h-pyrido(4',3':4,5)thieno(3,2-f)(1,2,4)triazolo(4,3-a)(1,4)diazepine, 7,8,9,10-tetrahydro-6-(2-chlorophenyl)-9-(cyclopropylcarbonyl)-1,4-dimethyl-, (s)-
e-6123
CHEMBL114014
6-(2-chlorophenyl)-3-cyclopropanecarbonyl-8,11-dimethyl-2,3,4,5-tetrahydro-8h-pyrido(4',3'-4,5)-thieno-(3,2-f)-1,2,4-triazolo(4,3-a)(1,4)diazepine
131614-02-3
DTXSID20157146
e-?6123
HY-10164
CS-0002491
(s)-(6-(2-chlorophenyl)-1,4-dimethyl-7,10-dihydro-4h-pyrido[4',3':4,5]thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-9(8h)-yl)(cyclopropyl)methanone
[(7s)-9-(2-chlorophenyl)-3,7-dimethyl-17-thia-2,4,5,8,14-pentazatetracyclo[8.7.0.02,6.011,16]heptadeca-1(10),3,5,8,11(16)-pentaen-14-yl]-cyclopropylmethanone
4h-pyrido[4',3':4,5]thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine, 6-(2-chlorophenyl)-9-(cyclopropylcarbonyl)-7,8,9,10-tetrahydro-1,4-dimethyl-, (4s)-
AKOS040741680

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
"00 h and the half-life for each animal was almost the same as that after intravenous administration."( Development of radioimmunoassay for the novel platelet activating factor receptor antagonist, E6123, and its application to pharmacokinetics in laboratory animals.
Abe, Y; Ida, S; Kagei, Y; Kusano, K; Miyazawa, S; Tadano, K; Tanaka, S; Ueda, M; Yuzuriha, T, 1994
)
0.29

Dosage Studied

ExcerptRelevanceReference
" dosing (1 mg/kg), the plasma concentration-time curves fitted a two-compartment model."( Pharmacokinetics of a new thienodiazepine platelet activating factor receptor antagonist (E6123) in laboratory animals. Is there a metabolic polymorphism in the rhesus monkey?
Abe, Y; Ida, S; Kusano, K; Tanaka, S; Yuzuriha, T, 1993
)
0.29
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID212616In vitro inhibition of Thromboxane A2 synthase was determined by inhibiting TXB2 production by incubating prostaglandin H2 (PGH-2) with human platelet microsomes; Not tested2002Bioorganic & medicinal chemistry letters, Feb-11, Volume: 12, Issue:3
Approach to dual-acting platelet activating factor (PAF) receptor antagonist/thromboxane synthase inhibitor (TxSI) based on the link of PAF antagonists and TxSIs.
AID160937In vitro inhibition of platelet activating factor induced platelet aggregation in rabbit platelet rich plasma.2002Bioorganic & medicinal chemistry letters, Feb-11, Volume: 12, Issue:3
Approach to dual-acting platelet activating factor (PAF) receptor antagonist/thromboxane synthase inhibitor (TxSI) based on the link of PAF antagonists and TxSIs.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (26)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's20 (76.92)18.2507
2000's6 (23.08)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 16.01

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index16.01 (24.57)
Research Supply Index3.37 (2.92)
Research Growth Index4.19 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (16.01)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (3.57%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other27 (96.43%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]